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NeurodegenerationAmyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease characterized by the selective
degeneration of upper and lower motor neurons associated with the abnormal aggregation of ubiquitinated
proteins. The molecular mechanisms underlying the pathogenesis of ALS remain unclear, however. Autophagy
is a major pathway for the elimination of protein aggregates and damaged organelles and therefore contributes
to cellular homeostasis. This catabolic process begins with the formation of the double membrane-bound
autophagosome that engulfs portions of the cytoplasm and subsequently fuses with a lysosome to form an
autolysosome, in which lysosomal enzymes digest autophagic substrates. Defects at various stages of autophagy
have been associated with pathological mutations of several ALS-linked genes including SOD1, p62, TDP-43, and
optineurin, suggesting that such defects may play a causative role in the pathogenesis of this condition. In this
review, we summarize the dysregulation of autophagy associated with ALS as well as potential therapeutic
strategies based on modulation of the autophagic process.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS)1 is an adult-onset neurological
disorder that is characterized by muscle weakness and atrophy, paraly-
sis, and eventual death by respiratory failure andwhich results from the
selective degeneration of upper and lower motor neurons that project
from the spinal cord, brain stem, and motor cortex [1]. Most cases of
ALS are sporadic, with ~10% of patients experiencing a familial form of
the disease [1]. Both sporadic and familial cases share similar clinical
characteristics.
A pathological hallmark of ALS is the presence of cytoplasmic
inclusions or protein aggregates in affected motor neurons [2], suggest-
ing that impairment of protein degradation plays a role in the disease
process. Unlike mitotic cells, which are able to clear aggregates of intra-
cellular proteins through their dilution or asymmetric distribution
during cell division [3], postmitotic neurons rely on two major
pathways of protein degradation for aggregate removal: the
ubiquitin-proteasome system (UPS) and autophagy-associated lyso-
somal degradation. Whereas the UPS mostly mediates the degradation
of short-lived proteins conjugated with ubiquitin, the autophagy-
based system preferentially targets long-lived proteins and damaged@korea.ac.kr (E.-J. Choi).
LAMP2, lysosome-associated
al structure; UPS, ubiquitin-organelles [4]. Dysfunction of these two pathways has been implicated
in the pathogenesis of various neurodegenerative diseases including
ALS [4].
Although the precise role of autophagy in the pathogenesis of ALS is
still under controversy, emerging evidence supports the notion that
defects in autophagic ﬂux may contribute to the demise of motor
neurons and disease progression in ALS [5]. Various stages of the
autophagy-dependent lysosomal degradation of protein aggregates
may be impaired in individuals with this disease. In this review, we
summarize the case for a potential role of autophagic dysfunction in
the pathogenesis of ALS.
2. Autophagic processing
Autophagy is a catabolic process that is highly conserved from yeast
and fungi to plants and mammals and which is responsible for the
lysosomal degradation of proteins and damaged organelles [6].
Autophagy has been classiﬁed into three subtypes on the basis of
how cargo is delivered to lysosomes: chaperone-mediated autophagy,
microautophagy, and macroautophagy [7]. In chaperone-mediated
autophagy, substrate proteins interact with lysosome-associated mem-
brane protein type 2 (LAMP2) and are subsequently transported into
the lysosomal lumen for degradation [8]. Such substrates contain a
consensus pentapeptidemotif (KFERQ) that is recognized by a cytosolic
chaperone, heat shock cognate 70 (HSC70) [9]. Microautophagy
refers to the direct engulfment of cytoplasmic cargo by an autophagic
tube, which forms by invagination of the lysosomal membrane and
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(hereafter referred to as autophagy) is mediated by a rearrangement
of subcellular membranes that results in the envelopment of cytosol
or organelles for delivery into lysosomes, where the enveloped cargo
is digested and recycled [6].
Autophagy is initiated by the formation of a phagophore (or isolation
membrane) in a manner dependent on multiple signaling molecules
(Fig. 1). The phagophore undergoes elongation and is transformed into
a double membrane-bound autophagosome [7]. The autophagosome
is transported along a microtubule track toward the microtubule-
organizing center, around which lysosomes are enriched [11]. During
this trafﬁcking process, the autophagosome undergoes fusion ﬁrst with
endosomal vesicles ormultivesicular bodies (also knownas amphisomes)
and then with a lysosome, resulting in formation of an autolysosome.
Finally, the contents of the autophagosome are digested by lysosomal
acidic hydrolases, yielding basic metabolites that can be used for new
synthetic processes or as an energy source. Many key regulators of
autophagy, termed autophagy-related (Atg) proteins,wereﬁrst identiﬁed
in yeast but are evolutionarily conserved from yeast to mammals [12].
The autophagic process may be divided into three main stages:
initiation, maturation, and degradation. Defects at any of these stages
may give rise to neurodegeneration including that associated withFig. 1. Three key stages in the process of autophagy. A. The initiation stage of autophagy includes
and closure of this structure to form a double membrane–bound vacuole, and formation of the
manner dependent on regulation by the ULK1 complex (ULK1, Atg13, FIP200) and the PI3K CIII
assembly site. Elongation of the phagophore is regulated by two types of ubiquitination-like reac
of Atg7, Atg10, and Atg16. Docking of the conjugate on the phagophore promotes the second u
LC3. This conjugation facilitates closure of the inner and outer bilayers of the phagophore. B. T
with endocytic compartments (late endosomes and amphisomes) and a lysosome to form th
along a microtubule track toward themicrotubule-organizing center in a manner dependent on
material in the autolysosome by acidic hydrolases originally present in the lysosome. AcidiﬁcatioALS [5,13,14]. We will now focus on each stage to shed light on the
potential role of autophagic defects in the pathogenesis of ALS.
3. ALS-associated defects at different stages of autophagy
3.1. Initiation stage: substrate recognition and autophagosome formation
Initiation of autophagy involves the rearrangement of subcellular
membranes to allow the sequestration of cargo as well as the consec-
utive formation of a protein-kinase autophagy regulatory complex
and a lipid–kinase signaling complex. The rearrangement of subcellular
membranes requires recruitment of Atg proteins to the phagophore and
leads to autophagosome formation. The initial event, referred to as
vesicle nucleation, is induced by phosphorylation (activation) of the
Unc51-like kinase 1 (ULK1)–Atg13–FIP200 complex under the control
of mammalian target of rapamycin (mTOR) complex 1 (mTORC1)
or AMP-activated protein kinase (AMPK) [15,16]. The activated
ULK1–Atg13–FIP200 complex promotes movement of a multiprotein
complex containing Beclin-1 (mammalian ortholog of yeast Atg6)
and class III phosphoinositide 3-kinase (PI3K CIII, also known as
Vps34) to the pre-autophagosomal structure (PAS), thereby triggering
autophagosome formation [17] (Fig. 1A). Elongation of the PAS and itsvesicle nucleation for a speciﬁcmembrane structure known as the phagophore, elongation
autophagosome. Inhibition of mTOR or activation of AMPK triggers vesicle nucleation in a
complex (Vps34, Vps15, Atg14, Beclin-1), both of which come together at the phagophore
tion. In theﬁrst reaction, Atg12 is covalently conjugatedwith Atg5 by the sequential actions
biquitination-like reaction, the covalent conjugation of phosphatidylethanolamine (PE) to
he maturation stage of autophagy involves the consecutive fusion of the autophagosome
e autolysosome. This stage begins with movement of the cargo-loaded autophagosome
the dynein–dynactin complex. C. The degradation stage includes the digestion of engulfed
n of the lysosome is highly dependent on v-ATPase, amultimeric proton-pumping enzyme.
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two ubiquitin-like conjugation systems: the Atg5–Atg12 conjugation
system and the microtubule-associated protein 1A/1B–light chain
3 (LC3) conjugation system [18]. The Atg5–Atg12 covalent conjugate,
whose formation is mediated by sequential action of the E1-like
enzyme Atg7 and the E2-like enzyme Atg10, possesses an E3-like
ligase activity that promotes the conjugation of LC3 to phosphatidyl-
ethanolamine to produce lipidated LC3-II, which localizes to the
autophagosomal membrane [19,20] (Fig. 1A). The lipidated LC3-II
remains membrane-anchored during subsequent autophagosome
maturation and serves as a key marker for this structure [21].
Genetic ablation of Atg5 or Atg7—both of which are required for
autophagosome formation—in the central nervous system of mice
gives rise to motor deﬁcits that are associated with the spontaneous
accumulation of ubiquitin-positive protein aggregates in motor
neurons, suggesting that defective autophagosome formation may
contribute to the pathogenesis of ALS [22,23]. Furthermore, an ALS-
linked mutant of superoxide dismutase 1 (SOD1) interacts with
Beclin-1 and thereby destabilizes its association with Bcl-xL and im-
pedes the initiation of autophagy, leading to a defective autophagy
ﬂux. This effect of the mutant SOD1 protein may be associated with
neurotoxicity in a mouse model of ALS [24] (Fig. 2A, Table 1).
Whereas autophagy contributes to the nonselective digestion of
cytosolic proteins, it also mediates the selective degradation of vari-
ous ubiquitin-conjugated substrates including protein aggregates,Fig. 2. Autophagy defects due to ALS-associated genemutations. A. Autophagy receptors such a
pathological mutations in p62 or OPTN disrupt such substrate recognition, resulting in a failure t
of protein aggregates and damaged mitochondria. B. Mutant SOD1 impedes the vesicle nuc
destabilization of the Beclin-1–Bcl-xL complex. C. Movement of the autophagosome along a m
of dynactin or dynein impair this trafﬁcking of the autophagosome. Furthermore, ALS-associate
D. Fusion between the autophagosome and a lysosomemay be disrupted by rare ALS-associated
the genes of the indicated proteins.intracellular organelles, and microorganisms [25,26]. Autophagy re-
ceptors bind the ubiquitinated cargo and link it to autophagosome-
associated ubiquitin-like proteins such as LC3 and GABARAP proteins
[27,28]. These receptors are thus thought to play a key role in recog-
nition of ubiquitinated cargo for engulfment, a process that appears
to be prone to disruption in neurodegenerative diseases [13,29].
Missense mutations in the autophagy receptor p62 (SQSTM1)
have been identiﬁed in both familial and sporadic cases of ALS [30].
Genetic ablation of p62 also results in an autophagy defect as well
as impaired locomotor activity such as swimming deﬁcits associated
with shorter motor axons in zebraﬁsh [31] (Fig. 2B, Table 1).
Moreover, p62 promotes the autophagy-dependent degradation
of an ALS-linked SOD1 mutant as well as aggregates of TAR DNA-
binding protein–43 (TDP-43), a major component of ALS-associated
cytoplasmic inclusions [32,33]. Rare ALS-associated mutations in the
gene for optineurin (OPTN), another autophagy receptor, interfere
with autophagy-mediated degradation of protein aggregates and dam-
aged mitochondria [34–36] (Fig. 2B, Table 1). TANK-binding kinase 1
(TBK1), which phosphorylates two autophagy receptors p62 and
OPTN [39,40], has been recently identiﬁed as another ALS-causing
gene [37,38]. The TBK1-mediated phosphorylation of the autophagy
receptors may modulate the recognition of autophagic cargoes by the
receptors, leading to a defect in autophagic ﬂux. A more detailed
mechanism by which TBK1 plays a role in the pathogenesis of ALS
needs to be further studied.s p62 and OPTN recognize diverse ubiquitin-conjugated autophagic substrates. ALS-linked
o load the ubiquitinated substrates into the autophagosome and consequent accumulation
leation step of autophagy through abnormal interaction with Beclin-1 and consequent
icrotubule track to a lysosome is dependent on the dynactin–dynein complex. Mutations
d SOD1mutants may also impair this process by targeting the dynactin–dynein complex.
mutations in the genes for VCP and CHMP2B. *, ALS-linkedmutations have been found in
Table 1




Vesicle nucleation SOD1 Mutant SOD1 impairs vesicle nucleation by destabilizing the Beclin-1–Bcl-xL complex [24]
Substrate recognition p62 (SQSTM1) Genetic ablation of p62 results in dysregulation of autophagy in zebraﬁsh [31]
OPTN OPTN mutation impedes autophagy-mediated protein degradation as well as mitophagy-mediated
clearance of damaged mitochondria
[34–36]
Autophagosome trafﬁcking Dynactin Dynactin mutation impedes autophagosome transport [48,49]
Dynein Dynein mutation impairs axonal transport of the autophagosome [52,53]
SOD1 Mutant SOD1 perturbs retrograde axonal transport by interacting with the dynactin–dynein complex [56]
Autophagosome–lysosome fusion VCP (p97) Mutation of VCP impairs autophagosome–lysosome fusion [58]
CHMP2B CHMP2B mutation impedes autophagosome–lysosome fusion [59,63]
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Maturation of the autophagosome into an autolysosome is a dynam-
ic process that includes serial fusion of the autophagosome ﬁrst
with late endosomes or amphisomes and then with a lysosome [41].
The maturation process requires vesicle trafﬁcking, which promotes
productive encounters of autophagosomes with lysosomes in a
microtubule- and dynein-dependent manner [42,43] (Fig. 1B). This
movement of the autophagosome in neurons is highly susceptible to
interruption, given that most autophagosomes are formed in axons
and that axon terminals are far from lysosomes in the cell body.
Movement of autophagosomes to the cell body thus requires retrograde
transport in neurons [44]. Impaired trafﬁcking gives rise to the abnor-
mal accumulation of autophagosomes and p62- or ubiquitin-positive
substrates in neurons and is implicated as a common pathology in
many neurodegenerative diseases [45,46].
Dynactin serves as an adaptor to link dynein with cargo along the
tracks of microtubules and thereby regulates the motor function of
dynein [47]. Point mutations in the gene for the p150 subunit of
dynactin have been found to give rise to motor neuron diseases
including familial ALS as a consequence of defects in the transport of
autophagosomes to lysosomes [48,49]. The accumulation of p62- or
ubiquitin-positive aggregates has been associated with reduced activity
of the dynactin–dynein complex in both clinical and experimental
studies [50,51] (Fig. 2C, Table 1). Defective dynein may also disrupt
retrograde transport of autophagosomes to lysosomes and thereby
give rise to abnormal accumulation of aggregates. Thus, mutations in
the gene for dynein may be associated with the demise of motor
neurons in a mouse model of familial ALS [52,53] (Fig. 2C, Table 1).
Furthermore, mutant SOD1 interacts physically with the dynein com-
plex and perturbs retrograde axonal transport [54] (Fig. 2C, Table 1).
Thus, dysfunction of the dynactin–dynein complex may be implicated
in impaired maturation of autophagosomes in ALS. However, a role of
dynein in the pathogenesis of ALS appears to be more complicated
than expected. In this regard, it is noteworthy to mention that Legs
at odd angles (Loa) mutation in cytoplasmic dynein heavy chain
(Dync1h1) delays disease onset and extends the life span in
SOD1(G93A) mice partly due to improvement of mitochondrial
abnormality shown in the mice [55,56].
The fusion of autophagosomes with lysosomes requires vari-
ous non-Atg proteins including ATPases, endosomal sorting com-
plexes required for transport (ESCRT), Rab proteins, and soluble
N-ethylmaleimide-sensitive factor-activating protein receptor
(SNARE) proteins [57]. The fusion process may be also affected by
ALS-linked mutations in the genes for valosin-containing protein
(VCP, also known as p97) and charged multivesicular body protein 2B
(CHMP2B) [58,59]. VCP is a member of the AAA-type ATPase family
and interacts with various ubiquitin-conjugated proteins, thereby
facilitating recycling or degradation of proteins either by the UPS or
by the autophagy-dependent lysosome system [60]. Loss of VCP activity
results in the accumulation of immature autophagosomes containing
ubiquitin-positive substrates [61,62] (Fig. 2D, Table 1). Similar tothose in the VCP gene, mutations in the gene for CHMP2B (ESCRT-III
subunit) lead to ALS and frontotemporal dementia presumably through
impairment of the autophagosome–lysosome fusion process [59,63]
(Fig. 2D, Table 1). Ectopic expression of disease-linkedmutants of either
VCP or CHMP2B in cultured neurons results in an increase in the
number of autophagosomes with p62-positive substrates as well as
cytoplasmic accumulation of TDP-43 [61,64,65], suggesting that
fusion-related ATPase and ESCRT proteins play an important role
in the regulation of autophagosomal maturation and intracellular
dynamics of TDP-43.
Ectopic P granules protein 5 homolog (Epg5), which is associated
with autophagosome maturation and endocytic trafﬁcking [66], is also
implicated in ALS pathogenesis. Genetic ablation of Epg5 in mice
thus gives rise to ALS-like features such as functional impairment of
the endosomal sorting complex and accumulation of nondegradative
autophagic vacuoles in association with selective degeneration both
of pyramidal neurons in cortical layer 5 and of spinal cord motor
neurons [67].3.3. Degradation stage: lysosomal clearance of autophagic substrates
A distinctive feature of lysosomes is their acidic lumen (pH 4.5–5.0),
which supports the efﬁcient catabolic function of hydrolytic enzymes
such as proteases, lipases, and nucleases [68]. Lysosomal acidiﬁcation
is maintained by a proton pump—the vacuolar ATPase (v-ATPase)—as
well as by lysosomal membrane proteins such as LAMP1 and LAMP2
that protect the lysosomal membrane from self-digestion [69]. Such
components thus contribute to the digestion of autophagic substrates
in the autolysosome (Fig. 1C). The integrity of the lysosomal membrane
is compromised under various neuropathologic conditions, suggesting
that lysosomal membrane proteins may be potential therapeutic
targets [69–71].
In addition to the direct role of lysosomes in the proteolytic degrada-
tion of autophagic substrates, lysosome biogenesis is linked to the
initiation stage of autophagy in a manner dependent on the basic
helix–loop–helix leucine-zipper transcription factor TFEB. TFEB thus
regulates the expression of genes related to lysosome biogenesis and
autophagosome formation [72]. mTORC1 interacts with and phosphor-
ylates TFEB under basal conditions and thereby prevents its transloca-
tion to the nucleus [73–75]. Such phosphorylation is also mediated by
extracellular signal-regulated kinase 2 (ERK2) and by the β isoform of
protein kinase C (PKCβ) [76,77]. In comparison, de-phosphorylation of
TFEB by calcineurin promotes its activation and nuclear translocation
[78]. Inhibition of mTORC1 activity triggers the activation of TFEB and
its translocation to the nucleus, resulting in trans-activation of its
target genes [73–76]. Manipulations that increase the trans-activation
activity of TFEB, including ectopic expression of TFEB or depletion
of its repressor ZKSCAN3, promote autophagic ﬂux by enhancing
both autophagosome formation and lysosome biogenesis [76,79].
Impairment of lysosomal function also appears to be associated
with the pathogenesis of Alzheimer's disease and Parkinson's
Table 2
Potential therapeutic effects of autophagy inducers in ALS.
Mode of action Autophagy inducer Therapeutic effects References
mTORC1 inhibition Rapamycin Attenuates ALS-like features and TDP-43 aggregation in TDP-43 transgenic animals [86–88]
Reduces accumulation of FUS-positive stress granules and neurodegeneration induced
by ALS-linked FUS mutation
[91]
Has no beneﬁcial effect in mutant SOD1 transgenic mice [92–94]
Has beneﬁcial effects in mutant SOD1 transgenic mice lacking mature lymphocytes [96]
Augments disease propagation in mutant VCP transgenic mice [95]
Tamoxifen Attenuates ALS-like features and TDP-43 aggregation in TDP-43 transgenic mice [87]
AMPK activation Lithium Has beneﬁcial effects in mutant SOD1 transgenic mice [99]
Has no effect in mutant SOD1 transgenic mice [100,101]
Trehalose Ameliorates ALS-like features in mutant SOD1 transgenic mice [107–110]
Unknown Spermidine Attenuate ALS-like features and TDP-43 aggregation in TDP-43 transgenic mice [87]
Carbamazepine
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relatively less studied in ALS.
4. Therapeutic modulation of autophagy in ALS
The evidence implicating defective autophagy in the pathogenesis
of neurodegenerative diseases supports enhancement of autophagy as
a potential therapeutic strategy. Such an approach might thus be ex-
pected to eliminate toxic protein aggregates in neurons by maintaining
lysosomal integrity or promoting autophagic ﬂux [83–85]. The potential
therapeutic effects of various inducers of autophagy in ALS are listed in
Table 2. Chronic administration of autophagy-inducing drugs such as
the mTOR inhibitor rapamycin protected motor neurons and improved
both motor performance and clearance of toxic TDP-43 aggregates in a
mousemodel of TDP-43 proteinopathy [86,87], although itsmechanism
is not fully understood. Beneﬁcial effects of rapamycin on lifespan and
locomotor activity were also apparent in a Drosophila model of ALS
with transgenic expression of dTDP, the Drosophila ortholog of TDP-
43 [88]. Several mutations in fused in sarcoma (FUS), a multifunctional
DNA/RNA binding protein, are associated with familial cases of ALS [89]
and cytosolic inclusions (aggregates) of these mutants are highly
localized in stress granules [90]. Rapamycin-induced autophagy not
only reduced the accumulation of FUS-positive stress granules, but
also prevented fragmentation of neurites and neurotoxicity in cultured
cortical neurons ectopically expressing ALS-linked FUS(R521C) [91].
In comparison, rapamycin failed to exhibit a beneﬁcial effect on motor
neuron survival in other ALS model mice expressing pathological
mutants of either SOD1 or VCP [92–95]. Moreover, chronic treatment
of rapamycin results in more severe impairment in mitochondrial
integrity, higher levels of pro-apoptotic Bax, and caspase-3 activation
in spinal motor neurons in SOD1(G93A)mice, all of whichmay contrib-
ute to demise of motor neurons [92]. Intriguingly, deﬁciency of mature
lymphocytes potentiated a therapeutic effect of rapamycin in ALS mice
expressing a human SOD1(G93A) transgene [96]. It remains unclear
how rapamycin has shown either protective or destructive effects in
different mouse models of ALS.
Activation of AMPK by mood stabilizers may be another route to
autophagy induction with potential beneﬁcial effects on several neuro-
degenerative diseases including ALS [97]. For example, several studies
have reported that lithium ameliorates ALS-like features in mice trans-
genic for an ALS-linked SOD1 mutant, presumably due to modulation
of various cellular processes including autophagy [98,99]. However,
the therapeutic effect of lithium on ALS should be interpreted with
caution. The beneﬁcial effect of lithium in mouse models [100,101]
and in clinical trials [102,103] is still controversial. In detail, while the
neuroprotective effect of lithium was observed at 0.4–0.8 mEq/l in
SOD(G93A) mice [98,99], the adverse effect was at over 1.0 mEq/l in
the same animals [100,101]. The disaccharide trehalose acts as a
chemical chaperone through AMPK activation, and it was found to
promote clearance of misfolded proteins and to confer neuroprotection
in models of proteinopathy induced by mutant forms of huntingtin,α-synuclein, or tau [104–106]. Administration of trehalose also facilitat-
ed induction of autophagy and autophagy-mediated degradation of
mutant SOD1, thereby alleviating the severity of disease [107–109].
Besides of stimulating AMPK, trehalose can induce heat shock protein
B8 (HspB8), which also facilitates autophagy with clearing autophagic
substrates including mutant SOD1 [110,111]. Collectively, these obser-
vations suggest that autophagy is a promising therapeutic target in
neurodegenerative diseases [112,113]. However, caution is warranted
in such targeting of autophagy in the development of therapeutics for
human diseases, given that most modulators of autophagy also have
diverse autophagy-independent effects. Potential side effects of such
drugs should therefore be thoroughly investigated.
5. Conclusion
Autophagy is a multistep degradative process that begins with
formation of the autophagosome in a manner dependent on sequential
regulation by the ULK1 complex (ULK1–Atg13–FIP200) and the PI3K
CIII complex (Vps34–Vps15–Atg14–Beclin-1). The autophagosome
loadedwith target substrates fuseswith late endosomes or amphisomes
and then with a lysosome to form the autolysosome, in which acidic
hydrolases degrade the autophagosome contents. Impairment of each
of these steps in the autophagy process has been associated with a
variety of human diseases including neurodegenerative disorders,
reﬂecting the importance of autophagic ﬂux for neuronal homeostasis.
The vesicle trafﬁcking responsible for transport of the autophagosome
to a lysosome is thought to be particularly susceptible to impairment
in neurons given the relatively long distances that separate these two
structures. Whereas malfunction of lysosomal hydrolases has been
associated with neurodegeneration, its contribution to ALS pathology
remains unclear.
A growing body of evidence implicates autophagy defects as a
potential cause of ALS pathology and therefore provides a basis for the
development of autophagy-targeted therapeutics. Impairment of
autophagy may occur at multiple steps in individuals with ALS. Given
that autophagy is required for a wide range of biological activities, not
only for adaptive responses to pathological stresses but also for mainte-
nance of intracellular homeostasis under physiological conditions,
drugs that target this process must be evaluated carefully for potential
side effects.
The nature of autophagy defects and their contribution to pathogen-
esis may differ among neurodegenerative diseases. It will be important
that future studies address these core defects, the cellular responses to
them, and their role in disease propagation. Such studies may provide
a sounder basis for the development of autophagy-modulating drugs.
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